Edition:
India

People: Exact Sciences Corp (EXAS.OQ)

EXAS.OQ on NASDAQ Stock Exchange Capital Market

106.87USD
17 Sep 2019
Change (% chg)

$0.00 (+0.00%)
Prev Close
$106.87
Open
--
Day's High
--
Day's Low
--
Volume
280
Avg. Vol
536,036
52-wk High
$123.94
52-wk Low
$53.09

Fallon, John 

Dr. John A. Fallon, M.D. is Independent Director of the Company. Dr. Fallon has served as a director since January 2016. Dr. Fallon served as Senior Vice President and Chief Physician Executive at Blue Cross Blue Shield of Massachusetts ("BCBS MA") from 2004 through 2015. Prior to his role at BCBS MA, Dr. Fallon served as Chief Executive Officer for clinical affairs at the State University of New York Downstate Medical Center, including University Hospital of Brooklyn and the clinical faculty practice plan. His professional experience also includes the Partners Healthcare System, where he was chairman of the physician network. Dr. Fallon was also the founder and CEO of North Shore Health System, a large physician-hospital organization in Massachusetts. He serves on the boards of directors of Insulet Corporation, a medical devices company (Nasdaq: PODD), AMAG Pharmaceuticals, Inc., a specialty pharmaceutical company (Nasdaq: AMAG) and Collegium Pharmaceuticals, Inc., a specialty pharmaceutical company (Nasdaq: COLL), as well as the board of Network for Excellence in Health Innovation (NEHI) (Chair), a not-for-profit institution. Dr. Fallon also previously served on the National Committee for Quality Assurance (NCQA) Medical Standards Committee (Chair) and the New England Comparative Effectiveness Public Advisory Council (CEPAC). Dr. Fallon practiced internal medicine for more than 20 years, fulfilled his residency at Boston City Hospital, is Board Certified in Internal Medicine and is a fellow of the American College of Physicians. Dr. Fallon earned a bachelor's degree from the College of the Holy Cross, an MBA from the University of South Florida and a Doctor of Medicine from Tufts University School of Medicine.

Basic Compensation

Total Annual Compensation, USD --
Restricted Stock Award, USD 199,969
Long-Term Incentive Plans, USD --
All Other, USD 69,000
Fiscal Year Total, USD 268,969

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Kevin Conroy

6,992,000

Jeffrey Elliott

1,983,860

Mark Stenhouse

3,862,260

D. Scott Coward

2,085,310

Graham Lidgard

2,084,980

Ana Hooker

--
As Of  31 Dec 2018